常山药业：公司艾本那肽注射液用于2型糖尿病的上市许可申请已获受理 能否上市及获批时间存在不确定性

Core Viewpoint - Changshan Pharmaceutical's application for the marketing authorization of Abemaciclib injection for type 2 diabetes has been accepted, but there is uncertainty regarding its approval and timeline [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of 147.69% from May 6 to June 9, which is over 30% deviation from the industry and ChiNext index growth [1] Group 2: Product Development - The application for clinical trials of Abemaciclib injection for weight loss indications has also been accepted, but there is uncertainty about receiving the approval notice [1]